Trimeris, Inc. : Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-24

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Trimeris is a biopharmaceutical company having the credit of successfully developing first fusion inhibitor: FUZEON, representing the first new class of anti-HIV treatments in seven years. As a part of its strategic initiatives in 2008, the company plans to: focus tightly on maximizing FUZEON's profitability by utilizing the resources and strengths of its collaborator, Roche.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Trimeris is primarily engaged in the discovery, development and commercialization of a class of antiviral drug treatments called fusion inhibitors. FUZEON, indicated for treating HIV/AIDS, is the only marketed product of Trimeris developed in collaboration with Roche.The company's lead product candidate, TRI-1144 is in preclinical research.

    Trimeris derives its revenues as royalties from Roche based on total net sales of FUZEON outside the US and Canada and collaboration income on FUZEON sales in the US and Canada. The company develops products utilizing its own or combined research efforts of its collaborators.

    Trimeris did not record any revenues during 2002-2004. The company's total revenues increased from $19 million in 2005 to $37 million in 2006. The company's biggest contributor to revenue growth during 2005-2006 was collaboration income on FUZEON sales in the US and Canada.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: fuzeon trimeris inc 1144 tri trimeris revenues competitors trimerisemployees swotanalysisfortrimeris

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.